AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33256540 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed self-contempt during brief psychiatric treatment
Number of subjects: 50
Study 33256540 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-contempt measure associated with weaker alliance rated by patients
Number of subjects: 50
Study 33256540 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-contempt measure associated with stronger alliance rated by therapists
Number of subjects: 50
Study 33256540 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-contempt expression
Number of subjects: 50
Study 34339653 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oxaliplatin with S‐1
Number of subjects: 0
Study 34339653 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant oxaliplatin with capecitabine
Number of subjects: 0
Study 34811623 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized-uncertainty intervention (what was currently unknown but that scientific uncertainty is expected)
Number of subjects: 449
Study 34811623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguity condition (emphasized what was currently unknown)
Number of subjects: 449
Study 34811623 — intervention group
Group type: COMPARATOR
Intervention: Control condition (what was currently known)
Number of subjects: 449
Study 32048083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib continuous treatment (10 mg twice daily)
Number of subjects: 198
Study 32048083 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib interrupted treatment (withdrawn for 2 weeks, then reinitiated)
Number of subjects: 198
Study 36409665 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge Developmental Support Program (PDSP)
Number of subjects: 44
Study 36409665 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44
Study 33411952 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with ischaemic compression technique (Group 1)
Number of subjects: 50
Study 33411952 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (Group 2)
Number of subjects: 50
Study 32049271 — intervention group
Group type: EXPERIMENTAL
Intervention: Elder-Friendly Approaches to the Surgical Environment (EASE) model
Number of subjects: 684
Study 35248048 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia™ group with H‐GIC (Equia Forte™)
Number of subjects: 40
Study 35248048 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐Equia™ group with H‐GIC (Equia Forte™)
Number of subjects: 40
Study 35248048 — intervention group
Group type: COMPARATOR
Intervention: Ketac™ group with H‐GIC (Ketac Universal™)
Number of subjects: 40
Study 35248048 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐Ketac™ group with H‐GIC (Ketac Universal™)
Number of subjects: 40
Study 33071088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate 50 mg/kg
Number of subjects: 80
Study 33071088 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 80
Study 35240317 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation (140 ml of concentrated NO3‐ beetroot juice, 9.7 mmol, 0.6 gm NO3‐)
Number of subjects: 13
Study 35240317 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation
Number of subjects: 13
Study 35240317 — intervention group
Group type: COMPARATOR
Intervention: NO3‐ depleted beetroot juice (placebo)
Number of subjects: 13
Study 32026846 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation programme including an exercise programme delivered at home.
Number of subjects: 0
Study 32026846 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional task practice, strategies to improve adherence, provision of appropriate aids and equipment.
Number of subjects: 0
Study 36440523 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 90
Study 36440523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloevera mouthwash
Number of subjects: 90
Study 36440523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouthwash)
Number of subjects: 90
Study 34242442 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 50000
Study 34242442 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with dietary modification
Number of subjects: 50000
Study 32353436 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Number of subjects: 554
Study 32353436 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 554
Study 34366317 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric contraction position for short right LLD
Number of subjects: 100
Study 34366317 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric contraction position for short left LLD
Number of subjects: 100
Study 34366317 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting position for short right LLD
Number of subjects: 100
Study 34366317 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting position for short left LLD
Number of subjects: 100
Study 33449120 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathewell (DCT intervention)
Number of subjects: 14978
Study 33449120 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 14978
Study 32655753 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling professional ethics principles (six counseling sessions)
Number of subjects: 84
Study 32655753 — intervention group
Group type: COMPARATOR
Intervention: Training manual (control group)
Number of subjects: 84
Study 34999850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average physical activity (PA) over 4 years
Number of subjects: 68132
Study 34999850 — intervention group
Group type: COMPARATOR
Intervention: Became active (PA baseline <9 MET-h/week to PA year 3 ≥9 MET-h/week)
Number of subjects: 68132
Study 34999850 — intervention group
Group type: COMPARATOR
Intervention: Remained active (PA baseline and PA year 3 ≥9 MET-h/week)
Number of subjects: 68132
Study 34999850 — intervention group
Group type: COMPARATOR
Intervention: Decreased activity (PA baseline ≥9 MET-h/week to PA year 3 <9 MET-h/week)
Number of subjects: 68132
Study 34077643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg intravenously every 2 weeks for up to 1 year)
Number of subjects: 709
Study 34077643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 35213469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic decision support accessed by anesthesia providers before or during surgery.
Number of subjects: 71
Study 35213469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative medications prescribed based on pharmacogenomic results.
Number of subjects: 71
Study 35213469 — intervention group
Group type: EXPERIMENTAL
Intervention: Total medications prescribed considering pharmacogenomic results.
Number of subjects: 71
Study 35213469 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomically high-risk medications administered.
Number of subjects: 71
Study 35213469 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomically cautionary medications administered.
Number of subjects: 71
Study 35213469 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider surveys on pharmacogenomic result accessibility.
Number of subjects: 71
Study 33022324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit & Strong! Plus (F&S! Plus)
Number of subjects: 413
Study 33022324 — intervention group
Group type: COMPARATOR
Intervention: Fit & Strong! (F&S!)
Number of subjects: 413
Study 36164414 — intervention group
Group type: EXPERIMENTAL
Intervention: CyclAGel 0.05%
Number of subjects: 627
Study 36164414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle eye drops
Number of subjects: 627
Study 32928503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for joint protection and physical activity with nursing support (n = 112)
Number of subjects: 224
Study 32928503 — intervention group
Group type: COMPARATOR
Intervention: Standard care for rheumatology (n = 112)
Number of subjects: 224
Study 35831218 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Clinic
Number of subjects: 86
Study 35831218 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 86
Study 33235055 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammar nail
Number of subjects: 120
Study 33235055 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Antirotation
Number of subjects: 120
Study 33235055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertrochanteric Antegrade Nail
Number of subjects: 120
Study 35739043 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivering peer support
Number of subjects: 58
Study 32449083 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 32449083 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 32449083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel fat pad thickness measurement using ultrasonography
Number of subjects: 1126
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel fat pad thickness measurement in males
Number of subjects: 1126
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel fat pad thickness measurement in females
Number of subjects: 1126
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with height and body mass in males
Number of subjects: 1126
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with age in males
Number of subjects: 1126
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with height and body mass in females
Number of subjects: 1126
Study 32745706 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with age in females
Number of subjects: 1126
Study 34935999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral erector spinae plane block (ESPB)
Number of subjects: 50
Study 32125536 — intervention group
Group type: EXPERIMENTAL
Intervention: Balafilcon A lens
Number of subjects: 37
Study 32125536 — intervention group
Group type: COMPARATOR
Intervention: Samfilcon A lens
Number of subjects: 37
Study 35850058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention (six sessions of hospital-based dance instruction and 16 weeks of home-based practice)
Number of subjects: 176
Study 35850058 — intervention group
Group type: COMPARATOR
Intervention: General health consultation (control group)
Number of subjects: 176
Study 35544244 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccine
Number of subjects: 2199
Study 33487188 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher scheme membership
Number of subjects: 1944
Study 33487188 — intervention group
Group type: COMPARATOR
Intervention: Non-recipients (Control)
Number of subjects: 1944
Study 33487188 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher scheme membership (for lowest socioeconomic group)
Number of subjects: 1944
Study 33487188 — intervention group
Group type: COMPARATOR
Intervention: Non-recipients (Control) in lowest socioeconomic group
Number of subjects: 1944
Study 32502088 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbered jerseys
Number of subjects: 48
Study 32502088 — intervention group
Group type: COMPARATOR
Intervention: Work attire (Control)
Number of subjects: 48
Study 32898930 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral Villalta score (cl-VS)
Number of subjects: 680
Study 32898930 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral Villalta score (cl-VS) > 4
Number of subjects: 680
Study 32898930 — intervention group
Group type: EXPERIMENTAL
Intervention: Postthrombotic syndrome (PTS)
Number of subjects: 680
Study 32898930 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between baseline cl-VS and ipsilateral Villalta score (VS)
Number of subjects: 680
Study 36884054 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nitroglycerin
Number of subjects: 94
Study 36884054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 33081531 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 3730
Study 33081531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 35546633 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 28
Study 35546633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 34274016 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial Navigator (PSN) intervention with monthly screening results and tailored recommendations for psychosocial distress and mental health symptoms.
Number of subjects: 0
Study 34274016 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 0
Study 36355991 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A) treatment (10U-25U for temporalis muscle and 30U-75U for masseter muscle)
Number of subjects: 14
Study 36355991 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A) treatment
Number of subjects: 14
Study 35935300 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave 4 Hz
Number of subjects: 108
Study 35935300 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave 20 Hz
Number of subjects: 108
Study 35935300 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended wave 4/20 Hz
Number of subjects: 108
Study 35260824 — intervention group
Group type: EXPERIMENTAL
Intervention: Care notebook plus peer support for 12 months
Number of subjects: 300
Study 35260824 — intervention group
Group type: COMPARATOR
Intervention: Care notebook (control)
Number of subjects: 300
Study 35972592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting risk of catheter-related thrombosis (CRT) based on logistic regression analysis
Number of subjects: 647
Study 35972592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting risk of CRT
Number of subjects: 647
Study 33891929 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy with extracorporeal urinary diversion (eRARC)
Number of subjects: 916
Study 33891929 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy with intracorporeal urinary diversion (iRARC)
Number of subjects: 916
Study 33891929 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 916
Study 33891929 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 916
Study 33891929 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 916
Study 33891929 — intervention group
Group type: EXPERIMENTAL
Intervention: pT-stage
Number of subjects: 916
Study 33891929 — intervention group
Group type: EXPERIMENTAL
Intervention: pN-stage
Number of subjects: 916
Study 33165612 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (15.8 mg/g)
Number of subjects: 0
Study 33165612 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (5.2 mg/g)
Number of subjects: 0
Study 33165612 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (2.4 mg/g)
Number of subjects: 0
Study 33165612 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (1.3 mg/g)
Number of subjects: 0
Study 33165612 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (0.4 mg/g)
Number of subjects: 0
Study 33055441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of ceramide-containing food (0.8 mg of dihydroceramide) for 12 weeks
Number of subjects: 0
Study 33517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 253
Study 33517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 253
Study 33517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CEVD
Number of subjects: 253
Study 33517534 — intervention group
Group type: COMPARATOR
Intervention: Both PCI and CABG
Number of subjects: 253
Study 34674222 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib 125 mg once daily (q.d.)
Number of subjects: 11
Study 34674222 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg q.d. plus erythromycin 500 mg three times daily for seven days
Number of subjects: 11
Study 35428210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated treatment arm (20 × 3 Gy)
Number of subjects: 538
Study 35428210 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated treatment arm (35 × 2 Gy)
Number of subjects: 538
Study 35428210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 538
Study 33078479 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (placebo-controlled trial)
Number of subjects: 19114
Study 36104548 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional preoperative teleconsent consultation
Number of subjects: 60
Study 36104548 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent on the day of surgery (Control)
Number of subjects: 60
Study 36104548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34443987 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for prenatal anxiety
Number of subjects: 27
Study 32516245 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC criteria
Number of subjects: 75
Study 32516245 — intervention group
Group type: EXPERIMENTAL
Intervention: PERCIST
Number of subjects: 75
Study 32516245 — intervention group
Group type: EXPERIMENTAL
Intervention: mRECIST
Number of subjects: 75
Study 35436329 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (3 days per week for 12 months)
Number of subjects: 103
Study 35436329 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity sham exercise control (3 days per week for 12 months)
Number of subjects: 103
Study 34172436 — intervention group
Group type: EXPERIMENTAL
Intervention: efpeglenatide 6 mg weekly (QW)
Number of subjects: 47
Study 34172436 — intervention group
Group type: EXPERIMENTAL
Intervention: efpeglenatide 16 mg monthly (QM)
Number of subjects: 47
Study 34172436 — intervention group
Group type: EXPERIMENTAL
Intervention: efpeglenatide 6 mg QW and 16 mg QM
Number of subjects: 47
Study 34172436 — intervention group
Group type: COMPARATOR
Intervention: liraglutide 1.8 mg daily (QD)
Number of subjects: 47
Study 35226547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Alteplase before Endovascular Thrombectomy
Number of subjects: 640
Study 33107645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (ABC model training)
Number of subjects: 130
Study 33375474 — intervention group
Group type: EXPERIMENTAL
Intervention: UAV-based RGB imagery methodology for yield estimation
Number of subjects: 0
Study 33375474 — intervention group
Group type: EXPERIMENTAL
Intervention: Yield estimation using UAV-based RGB imagery
Number of subjects: 0
Study 33375474 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial distribution analysis of fruit densities and weights
Number of subjects: 0
Study 34054617 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYCHOnlineTHERAPYfix (8 in-person sessions + 8 online self-help sessions)
Number of subjects: 900
Study 34054617 — intervention group
Group type: EXPERIMENTAL
Intervention: PSYCHOnlineTHERAPYflex (0 to 16 online self-help sessions)
Number of subjects: 900
Study 34054617 — intervention group
Group type: COMPARATOR
Intervention: Standard Cognitive Behavioral Therapy (CBT)
Number of subjects: 900
Study 34054617 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (PSYCHOnlineTHERAPYfix, PSYCHOnlineTHERAPYflex, and CBT)
Number of subjects: 900
Study 32040956 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (8 times per day)
Number of subjects: 74
Study 32040956 — intervention group
Group type: COMPARATOR
Intervention: Control (no honey)
Number of subjects: 74
Study 33726568 — intervention group
Group type: EXPERIMENTAL
Intervention: eCoFit physical activity intervention (20-week duration, including group sessions and smartphone app)
Number of subjects: 84
Study 33726568 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study 34992358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT) at 3 L/min via nasal cannula
Number of subjects: 32
Study 34992358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ambient air) at 3 L/min via nasal cannula
Number of subjects: 32
Study 32473338 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimney EVAR (CHEVAR) using Endurant stent-graft
Number of subjects: 165
Study 35125385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion) + DEX (0.5 µg/kg)
Number of subjects: 138
Study 35125385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Number of subjects: 138
Study 35125385 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (0.5 µg/kg)
Number of subjects: 138
Study 35125385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 138
Study 32739411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g phlorizin-rich apple extract (HIGH)
Number of subjects: 0
Study 32739411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.35 g phlorizin-rich apple extract (MED)
Number of subjects: 0
Study 32739411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g phlorizin-rich apple extract (LOW)
Number of subjects: 0
Study 32739411 — intervention group
Group type: COMPARATOR
Intervention: 0 g phlorizin-rich apple extract (CON)
Number of subjects: 0
Study 35014928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib-based therapy
Number of subjects: 498
Study 35014928 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil-based therapy
Number of subjects: 498
Study 33251662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic sub-threshold stimulation at 500 Hz (T500)
Number of subjects: 19